Vimarsana
Biggest News Aggregation in the World

Page 6 - Tim Franklin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tim Franklin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tim Franklin Today - Breaking & Trending Today

Local news outlets are struggling. What are some solutions? - Vimarsana News

Local news outlets are struggling. What are some solutions?

Legacy news sources are shifting revenue models, for-profit outfits are turning nonprofit and startups are finding opportunity in news deserts.

Chicago Public Media funder 'saddened' by layoffs but still optimistic Sun-Times, WBEZ merger will succeed - Vimarsana News

Chicago Public Media funder 'saddened' by layoffs but still optimistic Sun-Times, WBEZ merger will succeed

The MacArthur Foundation weighed in on the announced cuts to the public media company this week. Meanwhile, a City Council member was harshly critical of the move.

Is the US media layoffs phenomenon the next housing crisis? - Vimarsana News

Is the US media layoffs phenomenon the next housing crisis?

The media sector’s challenges amplify shadow banks’ toll on the US economy and mirror the 2008 housing crisis.

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss -March 25, 2024 at 06:56 am EDT - Vimarsana News

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss -March 25, 2024 at 06:56 am EDT

The following stocks are the leading risers and fallers on AIM in London on Monday. ---------- AIM - WINNERS ---------- ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug...

Incanthera says first order from skincare deal doubles - Vimarsana News

Incanthera says first order from skincare deal doubles

ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023. Shares in ImmuPharma were up 42% at 2.74 pence each in...